The letter from Hunt and Howden regarding our review1 illustrates the rapidly changing field of eradication therapy for Helicobacter pylori. Unfortunately, most of their comments are based on data published in abstract form after our paper was submitted for publication.
We agree that dual therapy is not an appropriate first-line treatment for H pylori infection and in our review we do not make that assertion. Instead, our intention was to alert the clinician to the suboptimal eradication rates of dual therapy compared with the superior triple and quadruple therapies, especially since 2 of the therapies listed have been approved by the Food and Drug Administration (ranitidine–bismuth citrate combination drug and clarithromycin and omeprazole-clarithromycin regimens), which may give clinicians a false sense of security.
Salcedo JA, Al-Kawas F. Treating Helicobacter pylori. Arch Intern Med. 1998;158(21):2396-2398. doi: